Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Five Prime Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 11, 2018-- Five Prime Therapeutics, Inc . (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker , Chief Executive Officer, will present at the
Toggle Summary Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster at the 2018 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 3, 2018-- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that a poster titled “FIGHT: A Phase 3 Randomized,

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Tuesday, January 09, 2018 4:30 PM PST

36th Annual J.P. Morgan Healthcare Conference

Summary Toggle Tuesday, January 09, 2018 4:30 PM PST

36th Annual J.P. Morgan Healthcare Conference

Speaker

Aron Knickerbocker
Chief Executive Officer
Summary Toggle Wednesday, February 14, 2018 11:30 AM EST